Get the Stockscreener App
403.95
0.64%
2.58
After Hours:
409.88
5.93
+1.47%
Natera Inc stock is traded at $403.95, with a volume of 1.10M.
It is up +0.64% in the last 24 hours and up +3.37% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$401.37
Open:
$399.945
24h Volume:
1.10M
Relative Volume:
0.90
Market Cap:
$58.23B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-246.13
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+2.67%
1M Performance:
+3.37%
6M Performance:
+100.83%
1Y Performance:
+107.15%
1-Day Range:
$395.33
$408.28
1-Week Range:
$383.76
$420.15
52-Week Range:
$181.00
$437.41
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
403.95 | 58.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
673.82 | 249.14B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
230.50 | 162.04B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
173.07 | 48.79B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
279.36 | 45.98B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Buy |
| Sep-08-26 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-26-26 | Resumed | Bernstein | Outperform |
| Jun-12-26 | Resumed | RBC Capital Mkts | Outperform |
| Jun-02-26 | Resumed | Wolfe Research | Outperform |
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media
After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria
Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan
Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media
$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK
Natera CEO Steven Chapman sells $526k in common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com UK
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan
Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com India
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
3 Reasons Investors Love Natera (NTRA) - TradingView
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Oct 16 '26 |
Sale |
402.47 |
1,500 |
603,710 |
8,250 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Oct 15 '26 |
Option Exercise |
10.41 |
50,000 |
520,500 |
2,169,394 |
| MATTHEW RABINOWITZ | Director |
Oct 15 '26 |
Proposed Sale |
394.75 |
50,000 |
19,737,500 |
0 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Oct 15 '26 |
Sale |
402.64 |
50,000 |
20,132,028 |
2,119,394 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Oct 01 '26 |
Sale |
414.22 |
3,000 |
1,242,645 |
106,914 |
| STEVEN L CHAPMAN | Officer |
Oct 01 '26 |
Proposed Sale |
413.31 |
1,273 |
526,144 |
0 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Oct 01 '26 |
Sale |
413.31 |
1,273 |
526,144 |
96,926 |
| SOLOMON MOSHKEVICH | Officer |
Oct 01 '26 |
Proposed Sale |
414.22 |
3,000 |
1,242,645 |
0 |
| Sheena Jonathan | CO-FOUNDER |
Sep 23 '26 |
Sale |
388.01 |
18,064 |
7,008,972 |
9,000 |
| Sheena Jonathan | Director |
Sep 23 '26 |
Proposed Sale |
387.55 |
21,064 |
8,163,402 |
0 |
0.47%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):